NCT06245980RecruitingNot Applicable
Role of SGLT2I in Diabetic Patients With Myocardial Infarction
Dongying Zhang1 site in 1 country1,200 target enrollmentStarted: January 1, 2018Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- Enrollment
- 1,200
- Locations
- 1
- Primary Endpoint
- Heart failure readmission
Study Overview
Brief Summary
Role of sglt2I in diabetic patients with myocardial infarction
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to 90 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Acute myocardial infarction patients
- •Type 2 diabetics.
Exclusion Criteria
- •Patients undergoing coronary artery bypass grafting (CABG).
- •Severe valvular heart disease.
- •Contraindications of secondary medical preventive therapy for myocardial infarction, such as β-blockers, angiotensin-converting enzyme inhibitors (ACEI)/ angiotensin-converting enzyme inhibitors (ARBs), antiplatelets, and statins.
- •Previously used SGLT2i.
- •Severe hepatic and renal insufficiency.
Arms & Interventions
With SGLT2I
Intervention: SGLT2 inhibitor (Drug)
Outcomes
Primary Outcomes
Heart failure readmission
Time Frame: 24months
Heart failure readmission
MACE
Time Frame: 24months
cardiovascular death and heart failure and myocardial infarction
Secondary Outcomes
- cardiovascular death(24months)
- Recurrent myocardial infarction(24months)
Investigators
Dongying Zhang
Professor
Chongqing Medical University
Study Sites (1)
Loading locations...
Similar Trials
Completed
Phase 3
SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular RiskType2 Diabetes MellitusNCT03151343Caroline M Kistorp92
Not yet recruiting
Not Applicable
The effect of SGLT2 inhibitor on diabetic cardiac autonomic neuropathydiabetes mellitusJPRN-UMIN000033541Sakakibara Heart Institute200
Recruiting
Not Applicable
The Effect of SGLT-2 Inhibitors on Epicardial Adipose Tissue and Cardiac Function in T2DM Patients With CAD (EpiCAD)Coronary Artery DiseaseNCT06128096Clinical Research Centre, Malaysia360
Unknown
Not Applicable
Lipid and Glycogen Metabolism in Patients With Impaired Glucose Tolerance and Calcium Sensing Receptor MutationsPrediabetes (Insulin Resistance, Impaired Glucose Tolerance)Familiar Hypocalcuric HypercalcemiaHealthy VolunteersType 2 Diabetes MellitusType 1 Diabetes MellitusNCT02023489Medical University of Vienna90
Unknown
Phase 4
Effects of SGLT2 Inhibitor on Type 2 Diabetic Patients Undergoing Cardiac SurgeryCardiac SurgeryDiabetes Mellitus, Type 2NCT04340908Hongchang Guo500